ScreenerHero

SNGXSoligenix, Inc.

NAS · US · Healthcare · Biotechnology · soligenix.com
0.4010USD+5.22%Mkt Cap: 8.73M $P/E: —

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized Bi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap8.73M $
Enterprise Value-1.24M $
Revenue (TTM)—
Gross Profit0 $
Net Income (TTM)-11.08M $
Revenue/Share—
Last Price0.4010 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.52
PEG—
EV/EBITDA0.11
EV/Revenue—
P/S—
P/B1.24
EPS (TTM)-0.72
EPS (Forward)-0.25
52W Range
0.28002% of range6.230
52W High6.230 USD
52W Low0.2800 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-209.37%
ROA-119.98%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.27M $
CapEx (TTM)5.88K $
FCF Margin—
FCF Yield-71.97%
Net Debt-9.51M $
Net Debt/EBITDA0.86
Balance Sheet
Debt/Equity0.07
Current Ratio2.77
Quick Ratio2.67
Book Value/Sh0.3070 USD
Cash/Share0.4510 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 7, 2016
Splits
Last Split1:16
Split DateJun 6, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.750 USD
Upside (mean)+336.4%
Target Range1.500 USD – 2.000 USD
$1.500+336.4% to mean$2.000
# Analysts2
Ownership
Shares Out.21.77M
Float21.66M
Insiders4.59%
Institutions6.72%
Short Interest
Short Ratio1.5d
Short % Float3.95%
Short % Out.3.95%
Shares Short585.02K
Short (prev mo.)409.41K
Technical
SMA 500.3856 (+4.0%)
SMA 2000.9460 (-57.6%)
Beta1.92
S&P 52W Chg18.16%
Avg Vol (30d)279.32K
Avg Vol (10d)140.40K
Technical Indicators
RSI (14)54.8
MACD-0.0013
MACD Signal-0.0058
MACD Hist.+0.0044
BB Upper0.4016 USD
BB Middle0.3790 USD
BB Lower0.3564 USD
BB Width11.91%
ATR (14)0.0229 USD
Vol Ratio (20d)4.70x